Literature DB >> 11935663

[Do primary care physicians know generalized anxiety disorders? Estimations of prevalence, attitudes and interventions].

K Beesdo1, P Krause, M Höfler, H U Wittchen.   

Abstract

This paper examines attitudes and characteristics of service providers for generalized anxiety disorders (GAD) in primary care. Based on a nationwide sample of 558 primary care doctors, the study found: 56.9% of all primary care doctors consider GAD to be an independent disorder, younger doctors more frequently than older ones. On average, they see on average at least 2.3 GAD definite patients a day. 27.4% indicate that they treat GAD differently than they treat depression. Doctors with frequent postgraduate courses on either depression or GAD reveal more favourable competence ratings with regard to recognition/diagnoses and therapy and refer such patients less frequently. Suggested treatments for GAD, however, are diffuse and by and large inconsistent with current research knowledge. Overall these findings suggest that the majority of primary care doctors view GAD as a prevalent independent disorder with special treatment needs.

Entities:  

Mesh:

Year:  2001        PMID: 11935663

Source DB:  PubMed          Journal:  Fortschr Med Orig


  3 in total

1.  The Hospital Anxiety and Depression Rating Scale: a cross-sectional study of psychometrics and case finding abilities in general practice.

Authors:  Ingrid Olssøn; Arnstein Mykletun; Alv A Dahl
Journal:  BMC Psychiatry       Date:  2005-12-14       Impact factor: 3.630

2.  General practitioners' self-perceived ability to recognize severity of common mental disorders: an underestimated factor in case identification?

Authors:  Ingrid Olssøn; Arnstein Mykletun; Alv A Dahl
Journal:  Clin Pract Epidemiol Ment Health       Date:  2006-08-30

3.  The Short Anxiety Screening Test in Greek: translation and validation.

Authors:  Ilias A Grammatikopoulos; Gary Sinoff; Athanasios Alegakis; Dimitrios Kounalakis; Maria Antonopoulou; Christos Lionis
Journal:  Ann Gen Psychiatry       Date:  2010-01-05       Impact factor: 3.455

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.